Regulated expression of antigen and/or regulated attenuation to enhance vaccine immunogenicity and/or safety

Patent metadata

Field	Value
Publication number	US-11920139-B2
Application number	US-202117500940-A
Country	US
Kind code	B2
Filing date	Oct 14, 2021
Priority date	May 10, 2007
Publication date	Mar 5, 2024
Grant date	Mar 5, 2024

Abstract

The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.

First claim

What is claimed is:

1. A recombinant bacterium capable of regulated expression of at least one nucleic acid sequence encoding a protein of interest, wherein the bacterium comprises:
a. at least one chromosomally integrated nucleic acid sequence encoding a repressor operably linked to a regulatable promoter, wherein the nucleic acid sequence encoding the repressor and/or promoter have been modified from the wild-type nucleic acid sequence so as to optimize the expression level of the nucleic acid sequence encoding the repressor,

wherein the repressor is selected from the group consisting of Lacl, C2, and C1,
wherein the regulatable promoter is selected from the group consisting of P rhaBAD , P xylAB , and P xylFGH ;
b. a vector comprising at least one nucleic acid sequence encoding a protein of interest operably linked to a promoter regulated by the repressor, such that the expression of the nucleic acid sequence encoding the protein is repressed during in vitro growth of the bacterium, but the bacterium is capable of high level expression of the nucleic acid sequence encoding the protein in a host; and
c. a deletion in pmi, wherein the deletion is Δpmi-2426.

2. The recombinant bacterium of claim 1 , wherein the bacterium further comprises a deletion in asd.

3. The recombinant bacterium of claim 1 , wherein the bacterium further comprises the mutation ΔasdA::TT araC PBAD c2.

4. The recombinant bacterium of claim 1 , wherein the nucleic acid sequence encoding the repressor comprises a modified Shine-Dalgarno sequence and optimized codons so as to optimize the expression level of the nucleic acid sequence encoding the repressor.

5. The recombinant bacterium of claim 1 , wherein the vector is a plasmid.

6. The recombinant bacterium of claim 1 , wherein the promoter regulated by the repressor is a Ptrc promoter.

7. The recombinant bacterium of claim 1 , wherein the protein of interest is toxic.

8. The recombinant bacterium of claim 1 , wherein the vector further comprises a nucleic acid sequence encoding a secretion signal for the protein of interest.

9. The recombinant bacterium of claim 1 , wherein the bacterium is capable of eliciting a protective immune response in the host.

10. The recombinant bacterium of claim 1 , wherein the bacterium comprises more than one means of attenuation.

11. The recombinant bacterium of claim 1 , wherein
the repressor is LacI;
the vector is a plasmid; and
the promoter regulated by the repressor is a Ptrc promoter.

12. The recombinant bacterium of claim 1 , further comprising a deletion in pabA and/or a deletion in pabB.

13. A composition comprising the recombinant bacterium of claim 1 .

14. A method for ameliorating one or more symptoms of a disease in a host, the method comprising administering to the host an effective amount of the composition of claim 12 .

15. A method for eliciting an immune response in a host, the method comprising administering to the host an effective amount of the composition of claim 12 .

Assignees

• The Arizona Board Of Regents For And On Behalf Of Arizona State Univ
• Washington University St Louis

Inventors

• Curtiss Iii Roy
• Wang Shifeng
• Wanda Soo-Young
• Kong Wei

Classifications

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• C12N15/74 Primary

  Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora · CPC title

• A61K35/74

  Bacteria (therapeutic use of a bacterial protein A61K38/00) · CPC title

• C12N1/36

  Adaptation or attenuation of cells · CPC title

• A61K2035/11

  Medicinal preparations comprising living procariotic cells · CPC title